semaglutide after may 22 🚨There's been a lot of confusion lately, so let's clear this up… Compounded GLP-1 medications (like and tirzepatide) are not banned entirely — but access is changing. The FDA has ended Semaglutide: Compounding pharmacies to end

Side Effect Profiles Gastrointestinal effects represent the most common adverse reactions for both medications

FDA approval is anticipated in 2026, through the FDA's national priority voucher program, positioning Lilly to compete aggressively in the oral segment

Just sayin' IF you wanted to take a supplement, you could do that in addition to the dietary measures

Other common experiences include constipation in 24% of users and occasional digestive upset

Adverse events occurred in 68% of the semaglutide 0.5 mg group, 62% of the dulaglutide 0.75 mg group, 69% of the semaglutide 1.0 mg group and 74% of the dulaglutide 1.5 mg group